Journal profile · Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Cancer Nanotechnology
ISSN 1868-6958 · eISSN 1868-6966 · Springer Vienna · AUSTRIA · Founded 2010
Cancer Nanotechnology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.71; fully open access; APC about USD 2,090; median 99 days to acceptance (94 articles, last 24 months); 57 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Cancer Nanotechnology is published by Springer Vienna and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Nanoparticle-Based Drug Delivery, Nanoplatforms for cancer theranostics and RNA Interference and Gene Delivery, together about 49.4% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
Cancer Nanotechnology is a peer-reviewed, open access journal aiming to disseminate cutting-edge research and promote emerging trends in the use of nanostructures and the induction of nanoscale processes for the prevention, diagnosis, treatment of cancer. Advance the frontier of nanotechnology in cancer treatment and diagnosis. Companion journal to Journal of Nanobiotechnology (IF 15.0). High visibility with open access. Served by a dedicated international editorial board to give thorough swift editorial response. Editor-in-Chief Hao Hong PhD View all editors
From the journal's Aims & Scope
Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
Editor-in-chief Hao HongPublisher website
Editorial board by country: 5 in mainland China (about 13%); most named United States 9, United Kingdom 9, Mainland China 5, South Korea 2, Germany 2 (38 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Nanoparticle-Based Drug DeliveryMaterials Science22%
- Nanoplatforms for cancer theranosticsEngineering19.5%
- RNA Interference and Gene DeliveryBiochemistry, Genetics and Molecular Biology7.8%
- Graphene and Nanomaterials ApplicationsEngineering4.8%
- Advanced biosensing and bioanalysis techniquesBiochemistry, Genetics and Molecular Biology4.2%
- Radiation Therapy and DosimetryMedicine4.2%
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology3.7%
- Advanced Nanomaterials in CatalysisMaterials Science3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Nanoscience & Nanotechnology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Nanoscience & Nanotechnology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Engineering Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Engineering | Zone 2 |
| Minor | Nanoscience & Nanotechnology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbaseCASPublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.71LetPub ·
- Impact factor (publisher) 2025
- 5.8Publisher website ·
- 5-year impact factor (publisher) 2025
- 5.4Publisher website ·
- CiteScore 2026-06
- 9.1LetPub ·
- SJR 2026-06
- 0.85LetPub ·
- SNIP 2026-06
- 0.77LetPub ·
- h-index
- 51OpenAlex ·
- i10-index
- 255OpenAlex ·
- 2-year mean citedness
- 6.61OpenAlex ·
- Self-citation rate
- 1.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 55LetPub ·
- Downloads per year (publisher) 2025
- 384,000Publisher website ·
Articles by year OpenAlex count · 481 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 72 | 72 | 27 |
| 2025 | 57 | 57 | 400 |
| 2024 | 62 | 62 | 836 |
| 2023 | 85 | 85 | 1,409 |
| 2022 | 56 | 56 | 764 |
| 2021 | 34 | 34 | 1,058 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
99 daysMedian, submission to acceptance · P25–P75 65 days – 152 days
- Acceptance to online
- median 18 days (94 articles)
- Submission to online
- median 115 days
- Sample
- 94 articles with submission and acceptance dates (140 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 15 weeksLetPub ·
- Submission to first decision
- 7 daysPublisher website ·
- Submission to publication (journal-reported)
- about 15 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 1,790 / USD 2,090 / GBP 1,490 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 1,990 / EUR 1,690 / GBP 1,390 | — | — | |
| LetPub | EUR 1,590 / USD 1,890 / GBP 1,340 | Yes | — | |
| Publisher website | GBP 1,490 / USD 2,090 / EUR 1,790 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare1 items from the author guidelines
- Suggested reviewers
- Optional
Article types accepted6
- brief reportFormatting guidelines for specific article types can be found below. Research Case Report Case Studies Methodology Review Brief ReportLength not stated
- case reportFormatting guidelines for specific article types can be found below. Research Case Report Case Studies Methodology Review Brief ReportLength not stated
- case studiesFormatting guidelines for specific article types can be found below. Research Case Report Case Studies Methodology Review Brief ReportLength not stated
- methodologyFormatting guidelines for specific article types can be found below. Research Case Report Case Studies Methodology Review Brief ReportLength not stated
- researchFormatting guidelines for specific article types can be found below. Research Case Report Case Studies Methodology Review Brief ReportLength not stated
- reviewFormatting guidelines for specific article types can be found below. Research Case Report Case Studies Methodology Review Brief ReportLength not stated
Policy excerpts from the journal's websiteAuthorship, Data availability, License & copyright, Open access, Peer review
- Authorship
Manuscript must be submitted by an author, not a third party. Model summary
Please note that a manuscript can only be submitted by an author of the manuscript and may not be submitted by a third party.
Source ↗Publisher website ·- Data availability Formatting the 'Availability of data and materials' section of your manuscript
Data sharing strongly encouraged or required; deposit in public repositories where available and appropriate. Model summary
The following format for the 'Availability of data and materials section of your manuscript should be used:
Source ↗Publisher website ·- License & copyright Licensing and copyright
Open access under CC BY-NC-ND or CC BY licence. Model summary
Creative Commons licences Open access articles in Springer Nature journals are published under Creative Commons licences. These provide an industry-standard framework to support easy re-use of open access material. Under Creative Commons licences, authors retain copyright of their articles. Cancer Nanotechnology articles are published open access under a CC BY-NC-ND (Creative Commons Attribution N…
Source ↗Publisher website ·- Open access Benefits of open access
Publishing open access (OA) offers a number of benefits, including greater reach and readership for your work: Cited more 1.6x more citations of OA articles than non-OA articles across all subjects Downloaded more 4x more downloads of OA articles than non-OA articles Greater impact 2.5x more Altmetric attention. OA articles attracted 1.9x more news mentions and 1.2x more policy mentions Open acces…
Source ↗Publisher website ·- Peer review Peer review policy
Peer review is the process used to evaluate the quality of a manuscript before publication. Independent researchers in the relevant field assess submitted manuscripts to check their validity and robustness. Their feedback guides editors in making publication decisions. Typically, two or more experts evaluate each manuscript based on three main criteria: scientific robustness: is the research metho…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Vienna
- Country or region
- AUSTRIA
- Language
- English
- Founded
- 2010
- ISSN
- 1868-6958
- Electronic ISSN
- 1868-6966
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Cancer Nanotechnology
What CAS zone is Cancer Nanotechnology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Cancer Nanotechnology is in Zone 3 of Medicine, and in Zone 3 of the minor category Nanoscience & Nanotechnology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Cancer Nanotechnology?
The latest impact factor listed by LetPub is 5.71; CiteScore 9.1, h-index 51.
How long does peer review take at Cancer Nanotechnology?
Based on the dates recorded on 94 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 99 days (interquartile range 65–152 days); authors report an average review time of about 15 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Cancer Nanotechnology based?
Of the 38 board members whose country the journal's board page names, 5 (about 13%) are in mainland China; the countries named most often are United States (9), United Kingdom (9) and Mainland China (5). Counted from the institutions listed on the board page; for reference only.
Which databases index Cancer Nanotechnology?
According to LetPub and DOAJ records, Cancer Nanotechnology is indexed in SCIE, Scopus and DOAJ. The journal's website also lists Embase and CAS; that list has not been checked against each database.
Is Cancer Nanotechnology open access, and what is the APC?
Cancer Nanotechnology is a fully open-access journal. APC about USD 2,090.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .